Rare disease

FDA review
#FDA #Paediatrics #Priority Review #Rare disease

Congress extends Rare Pediatric Disease Priority Review Voucher programme through 2029

Brian Malkin and Sadaf Deedar, Spencer Fane LLP, unpack the recent changes to the FDA’s Priority Review Voucher scheme and the upcoming review of its effectiveness in promoting drug development for rare paediatric diseases.  Congress recently enacted the Consolidated Appropriations Act, 2026 (CAA), which provided $1.2 trillion in funding for… Read More

#Exclusive Content #Regulatory

Blood cells
#Monoclonal antibodies #Phase II trial #Rare disease #Takeda

NEJM data support Takeda’s treatment for ITP

The New England Journal of Medicine (NEJM) has published final results from a Phase II study evaluating Takeda’s mezagitamab (TAK-079), an investigational treatment option for patients with primary immune thrombocytopenia (ITP).  The NEJM-published data showed patients treated with mezagitamab achieved:  … Read More

#News

Cell and gene therapy
#FDA #Gene therapy #Paediatrics #Rare disease #Rocket Pharmaceuticals

First gene therapy for rare paediatric disease gets US approval

The US Food and Drug Administration (FDA) has granted accelerated approval for Kresladi (marnetegragene autotemcel), an autologous haematopoietic stem cell-based gene therapy.  It is indicated for the treatment of paediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling… Read More

#News #Regulatory #Trending News

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

Stamp of approval
#Accelerated assessment #Ascendis Pharma #FDA #Paediatrics #Rare disease

FDA approves first once-weekly achondroplasia therapy

The US Food & Drug Administration (FDA) has granted approval for Yuviwel (navepegritide) under its Accelerated Approval Program.  Navepegritide is the only once-weekly treatment indicated to increase linear growth in children one years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic… Read More

#News #Regulatory

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

#Advanced Therapies #Cell and gene therapy #FDA #Gene therapy #Rare disease

FDA approves first gene therapy for Wiskott-Aldrich syndrome

The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for paediatric patients six months and older and adults with WAS who have a mutation in the WAS gene and for whom haematopoietic… Read More

#Editor's Choice #News #Regulatory

#Neurodevelopmental disorders #Neuroscience #Phase III trial #Rare disease #UCB

UCB reports positive results for neurodevelopmental disorder

Global biopharmaceutical company UCB has reported positive data for its Phase III GEMZ study which is investigating adjunctive fenfluramine in children and adults with CDKL5 Deficiency Disorder (CDD).   The data were announced at the American Epilepsy Society (AES) meeting, Atlanta, USA.  The results… Read More

#Editor's Choice #News

MHRA
#MHRA #Rare disease #Rare diseases #UK

UK commits to major regulatory reform for rare therapies

The rulebook for rare disease therapies will be overhauled to make it quicker and easier to get these therapies tested, manufactured and approved in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced.  The announcement came in a new paper supporting the ambitions of the UK Government’s… Read More

#News #Regulatory

Researcher in lab
#Acadia Pharmaceuticals #Clinical trial #Phase III trial #Rare disease

Acadia cancels development of intranasal carbetocin in rare disease

Acadia Pharmaceuticals has announced that its Phase III COMPASS PWS trial evaluating intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS) did not meet its primary endpoint.  The treatment did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from… Read More

#News

B-cells in multiple myeloma
#Cancer immunotherapy #Clinical development #CNS #Essential Pharma #Rare disease

New podcast: From established medicines to rare disease innovation

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Emma Johnson, CEO… Read More

#News

#Drug pricing #National Institute for Health and Care Excellence (NICE) #Rare disease

New NICE thresholds is good news for ultra-rare disease drugs, says biotech 

 The National Institute for Health and Care Excellence (NICE), the body that determines the clinical effectiveness and economic value of new medicines, has increased the cost-effectiveness thresholds it applies for drugs that qualify for their Highly Specialised Technology (HST) programme.  However, SynaptixBio, the only company licensed to commercialise a treatment for… Read More

#Business & Investment #News

#Clinical trial design #Clinical trials #Rare disease

Clinical trials in rare and life-limiting diseases

Dr Tony Lockett, Chief Medical Officer at Nevrargenics, explores the future of clinical trials in rare diseases. Clinical trials are in crisis. Over 80% of clinical trials over-run in costs and time and 60% of trials also do not make their endpoint. In this circumstance, it is hardly surprising that… Read More

#Exclusive Content

#FDA #Gene therapy #Phase II trial #Rare disease #Rocket Pharmaceuticals

FDA lifts hold on Rocket Pharma’s Phase II trial of RP-A501

The US Food and Drug Administration (FDA) has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase II trial of RP-A501 for the treatment of Danon disease.  The hold was lifted in under three months and led to an increase in  Rocket’s stock value by 30%. … Read More

#News

FDA
#FDA #Mitochondria #PTC Therapeutics #Rare disease

FDA rejects PTC Therapeutics’ drug for Friedreich’s ataxia

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) stating its decision not to recommend PTC Therapeutics’ vatiquinone for Friedreich's ataxia (FA).  The FDA stated in the CRL that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional adequate and well-controlled… Read More

#News #Regulatory